Vaccination Against Seasonal Influenza A/H3N2 Virus Reduces the Induction of Heterosubtypic Immunity Against Influenza A/H5N1 Virus Infection in Ferrets

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2011 Jan 14

PMID 21228239

Citations 55

Authors

R Bodewes

J H C M Kreijtz

M M Geelhoed-Mieras

G van Amerongen

R J Verburgh

S E van Trierum

T Kuiken

R A M Fouchier

A D M E Osterhaus

G F Rimmelzwaan

Affiliations

Soon will be listed here.

Abstract

Infection with seasonal influenza viruses induces a certain extent of protective immunity against potentially pandemic viruses of novel subtypes, also known as heterosubtypic immunity. Here we demonstrate that infection with a recent influenza A/H3N2 virus strain induces robust protection in ferrets against infection with a highly pathogenic avian influenza virus of the H5N1 subtype. Prior H3N2 virus infection reduced H5N1 virus replication in the upper respiratory tract, as well as clinical signs, mortality, and histopathological changes associated with virus replication in the brain. This protective immunity correlated with the induction of T cells that cross-reacted with H5N1 viral antigen. We also demonstrated that prior vaccination against influenza A/H3N2 virus reduced the induction of heterosubtypic immunity otherwise induced by infection with the influenza A/H3N2 virus. The implications of these findings are discussed in the context of vaccination strategies and vaccine development aiming at the induction of immunity to pandemic influenza.

Citing Articles

Infection with Seasonal H1N1 Influenza Results in Comparable Disease Kinetics and Host Immune Responses in Ferrets and Golden Syrian Hamsters.

Paterson J, Ryan K, Morley D, Jones N, Yeates P, Hall Y Pathogens. 2023; 12(5).

PMID: 37242338 PMC: 10222994. DOI: 10.3390/pathogens12050668.

Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.

Ng T, Flores-Malavet V, Mansoor M, Arvelo A, Dhume K, Prokop E J Immunol. 2023; 210(5):628-639.

PMID: 36645384 PMC: 9998374. DOI: 10.4049/jimmunol.2200393.

A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets.

van de Ven K, Lanfermeijer J, van Dijken H, Muramatsu H, Vilas Boas de Melo C, Lenz S Sci Adv. 2022; 8(50):eadc9937.

PMID: 36516261 PMC: 9750153. DOI: 10.1126/sciadv.adc9937.

Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model.

Baek K, Maharjan S, Akauliya M, Thapa B, Kim D, Kim J PLoS One. 2022; 17(10):e0275722.

PMID: 36215268 PMC: 9550053. DOI: 10.1371/journal.pone.0275722.

Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine.

Marriott A, Gooch K, Brown P, Ryan K, Jones N, Merredew N NPJ Vaccines. 2021; 6(1):43.

PMID: 33782409 PMC: 8007727. DOI: 10.1038/s41541-021-00306-7.

References

Bodewes R, Kreijtz J, Rimmelzwaan G . Yearly influenza vaccinations: a double-edged sword?. Lancet Infect Dis. 2009; 9(12):784-8. DOI: 10.1016/S1473-3099(09)70263-4. View

Grebe K, Yewdell J, Bennink J . Heterosubtypic immunity to influenza A virus: where do we stand?. Microbes Infect. 2008; 10(9):1024-9. PMC: 2584237. DOI: 10.1016/j.micinf.2008.07.002. View

Lemaitre M, Carrat F . Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis. 2010; 10:162. PMC: 2896934. DOI: 10.1186/1471-2334-10-162. View

Smallman-Raynor M, Cliff A . Avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis. 2007; 13(3):510-2. PMC: 2141519. DOI: 10.3201/eid1303.060849. View

Nicholson K, Colegate A, Podda A, Stephenson I, Wood J, Ypma E . Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001; 357(9272):1937-43. DOI: 10.1016/S0140-6736(00)05066-2. View

Nguyen H, van Ginkel FW , Vu H, McGhee J, Mestecky J . Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis. 2001; 183(3):368-76. DOI: 10.1086/318084. View

Park C, Ishinaka M, Takada A, Kida H, Kimura T, Ochiai K . The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice. Arch Virol. 2002; 147(7):1425-36. DOI: 10.1007/s00705-001-0750-x. View

Rimmelzwaan G, Kuiken T, van Amerongen G, Bestebroer T, Fouchier R, Osterhaus A . Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol. 2001; 75(14):6687-91. PMC: 114392. DOI: 10.1128/JVI.75.14.6687-6691.2001. View

Bodewes R, Kreijtz J, Hillaire M, Geelhoed-Mieras M, Fouchier R, Osterhaus A . Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol. 2010; 91(Pt 7):1743-53. DOI: 10.1099/vir.0.020784-0. View

10.

ONeill E, Krauss S, Riberdy J, Webster R, Woodland D . Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol. 2000; 81(Pt 11):2689-2696. DOI: 10.1099/0022-1317-81-11-2689. View

11.

Janjua N, Skowronski D, Hottes T, Osei W, Adams E, Petric M . Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis. 2010; 51(9):1017-27. PMC: 7107856. DOI: 10.1086/656586. View

12.

Laurie K, Carolan L, Middleton D, Lowther S, Kelso A, Barr I . Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis. 2010; 202(7):1011-20. DOI: 10.1086/656188. View

13.

Schotsaert M, De Filette M, Fiers W, Saelens X . Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8(4):499-508. PMC: 2706389. DOI: 10.1586/erv.09.6. View

14.

Zitzow L, Rowe T, Morken T, Shieh W, Zaki S, Katz J . Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol. 2002; 76(9):4420-9. PMC: 155091. DOI: 10.1128/jvi.76.9.4420-4429.2002. View

15.

Rimmelzwaan G, Baars M, Claas E, Osterhaus A . Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 1998; 74(1):57-66. DOI: 10.1016/s0166-0934(98)00071-8. View

16.

Bernstein D, Edwards K, Dekker C, Belshe R, Talbot H, Graham I . Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008; 197(5):667-75. DOI: 10.1086/527489. View

17.

Govorkova E, Rehg J, Krauss S, Yen H, Guan Y, Peiris M . Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol. 2005; 79(4):2191-8. PMC: 546577. DOI: 10.1128/JVI.79.4.2191-2198.2005. View

18.

Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

19.

Kreijtz J, Bodewes R, van den Brand J, de Mutsert G, Baas C, van Amerongen G . Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine. 2009; 27(36):4983-9. DOI: 10.1016/j.vaccine.2009.05.079. View

20.

Kelly H, Barr I . Large trials confirm immunogenicity of H1N1 vaccines. Lancet. 2009; 375(9708):6-9. DOI: 10.1016/S0140-6736(09)62132-2. View